Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

The Pharmacokinetics of Opioids and Sedative/Hypnotics During Selective Cerebral Perfusion

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Ervant V. Nishanian, Columbia University
ClinicalTrials.gov Identifier:
NCT00494598
First received: June 28, 2007
Last updated: July 31, 2013
Last verified: October 2008

June 28, 2007
July 31, 2013
March 2007
Not Provided
Pharmacokinetics of intra-carotid opioids and sedatives during selective cerebral perfusion [ Time Frame: one week ] [ Designated as safety issue: Yes ]
Pharmacokinetics of intra-carotid opioids and sedatives during selective cerebral perfusion [ Time Frame: one week ]
Complete list of historical versions of study NCT00494598 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
The Pharmacokinetics of Opioids and Sedative/Hypnotics During Selective Cerebral Perfusion
The Pharmacokinetics of Opioids and Sedative/Hypnotics During Selective Cerebral Perfusion

There is a need to understand how long anesthetic drugs last in the brain during surgery on the ascending aorta or aortic arch. Drugs can have a prolonged effect when blood temperature is made cold therefore the influence of temperature needs to be studied. This type of surgery allows us to answer questions about how anesthetic drugs behave when they are given during a routine portion of surgery. Patients will be provided with anesthetic drugs during surgery while on a heart lung machine. After the drug is injected into the heart lung machine it will be delivered to the brain to provide more sleep and pain relief. Immediately after the injection of anesthetic drugs, blood samples will be taken from an existing intravenous line in the neck and plasma drug concentrations measured. This will help us to understand how long drugs last in the brain during this type of surgery.

The purpose of this study is to understand the disposition of sufentanil, midazolam and morphine when the drugs are introduced into the arterial circulation of the brain. Patients undergoing surgery on the ascending aorta or aortic arch often require cessation of blood flow to the organs of the body, while maintaining some degree of blood flow to the brain. In order to achieve organ protection during the circulatory arrest phase of surgery, the body is cooled to a core temperature of 28°C. Various techniques including deep hypothermic circulatory arrest, retrograde cerebral perfusion through the superior vena cava, and partial or bilateral antegrade selective cerebral perfusion have been proposed as means to protect the brain from ischemic injury during surgery on the aortic arch. At our institution selective cerebral perfusion has found success for major aortic surgery. This technique was devised and first employed by DeBakey and associates, to protect the brain during aortic arch surgery with bilateral carotid perfusion [1]. Selective cerebral perfusion requires the surgical construction and placement of a Dacron graft onto the right axillary artery that when connected to a cardiopulmonary bypass machine it will provide 10 ml/kg/min antegrade flow for brain perfusion [2]. Cerebral cooling will also decrease the oxygen demand of the brain. In such a way brain ischemia may be minimized. The nature of major aortic arch surgery requires independent cerebral circulation or selective cerebral perfusion for a finite period of time. The cardiopulmonary bypass machine is allowed to perfuse the brain indirectly by serial flow through the right axillary artery to the innominate artery and finally to the right carotid artery. Any anesthetic drug that is introduced into the cardiopulmonary bypass circuit will be delivered the same way. We will take advantage of this independent circuit to safely deliver anesthetic drugs to the brain via the right carotid artery during surgery.

A prior study that enrolled 6 patients has shown that the anesthetic administration is safe and feasible. Patients had no problems related to anesthesia or surgery. All patients left the hospital in stable condition.

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Description:

Plasma

Non-Probability Sample

all patients undergoing aortic arch surgery

Aortic Aneurysm
Drug: Sufentanil
200 mcg intra-arterial one time bolus
Other Name: sufenta
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
6
June 2007
Not Provided

Inclusion Criteria:

  • The study population will comprise individuals who have elected to undergo aortic arch surgery or re-operative cardiac surgery requiring selective cerebral perfusion.
  • Patients will be treated according to the standard medical practice of Columbia University Medical Center.
  • Patients will be within 21 to 90 years of age.

Exclusion Criteria:

  • Patients having known hypersensitivity to the anesthetic agents being studied will be excluded.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00494598
AAAC2983
No
Ervant V. Nishanian, Columbia University
Columbia University
Not Provided
Principal Investigator: Ervant Nishanian, PhD MD Columbia University College of Physicians and Surgeons
Columbia University
October 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP